Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.610
-0.130 (-7.47%)
At close: Mar 6, 2026, 4:00 PM EST
1.640
+0.030 (1.86%)
After-hours: Mar 6, 2026, 7:04 PM EST
Ocugen Revenue
In the year 2025, Ocugen had annual revenue of $4.41M with 8.83% growth. Ocugen had revenue of $-193.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$4.41M
Revenue Growth
+8.83%
P/S Ratio
119.62
Revenue / Employee
$46,453
Employees
95
Market Cap
527.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.41M | 358.00K | 8.83% |
| Dec 31, 2024 | 4.06M | -1.98M | -32.82% |
| Dec 31, 2023 | 6.04M | 3.55M | 142.60% |
| Dec 31, 2022 | 2.49M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 43.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 8.00K | -18.00K | -69.23% |
| Dec 31, 2012 | 26.00K | -97.00K | -78.86% |
| Dec 31, 2011 | 123.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOCGN News
- 2 days ago - Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 days ago - Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa - GlobeNewsWire
- 25 days ago - Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering - Benzinga
- 6 weeks ago - Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage - Benzinga
- 7 weeks ago - Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire